Drugs / TD-5202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04044339 | Aug → Nov 2019 | — | Theravance Biopharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TD-5202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04044339 ↗ |
| Route | Oral | “Study Drug to be administered orally” NCT04044339 ↗ |